1
|
Wood CJ, Selmic LE, Schlag AN, Bacmeister C, Séguin B, Culp WTN, Ayres SA, Sumner JP, Byer B, Mayer UK, Liptak JM. Biological behaviour and clinical outcome in 42 cats with sarcoids (cutaneous fibropapillomas). Vet Comp Oncol 2020; 18:699-705. [PMID: 32304135 DOI: 10.1111/vco.12598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 04/03/2020] [Accepted: 04/13/2020] [Indexed: 12/01/2022]
Abstract
Feline sarcoids (or cutaneous fibropapillomas) are rare dermal neoplasms. There are currently no reported statistics concerning their clinical behaviour. Our objective with this retrospective, multi-institutional study was to describe the clinical presentation and biological behaviour of sarcoids in cats and to determine the oncologic outcome following surgical resection. Medical records from a laboratory database and six contributing institutions were searched to identify cats with histologically confirmed sarcoids. Forty-two cats were included in the study. The majority of sarcoids occurred on the face, particularly rostral locations such as the lips and nasal planum. Complete and incomplete histologic excision was achieved in 18 and 21 cats, respectively. The overall local recurrence rate was 40.5%. Complete histologic excision was associated with a significantly lower local recurrence rate (11.1%) and longer disease-free interval (not reached) compared with cats with incompletely excised sarcoids (66.7% and 250 days, respectively). The 1- and 2-year local recurrence rates were 0% and 7%, respectively, for cats with complete histologic excision, and 67% at both time intervals for cats with incomplete histologic excision. Five of the cats (83.3%) treated with curative-intent surgical revision following local tumour recurrence had no further local recurrence. All cats that died secondary to tumour-related causes had initial incomplete histologic excision and were euthanized because of local recurrence. Wide surgical resection of feline sarcoids is recommended to achieve complete histologic excision, local tumour control and a potential cure. For cats with incomplete histologic excision or local tumour recurrence, repeat surgical resection is recommended.
Collapse
Affiliation(s)
| | - Laura E Selmic
- Department of Veterinary Clinical Science, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA
| | - Ariel N Schlag
- Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi, USA
| | | | - Bernard Séguin
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA
| | - William T N Culp
- School of Veterinary Medicine, University of California, Davis, California, USA
| | - Sara A Ayres
- Mapleview Animal Clinic, Barrie, Ontario, Canada
| | - Julia P Sumner
- Department of Clinical Sciences, Cornell University, College of Veterinary Medicine, Ithaca, New York, USA
| | - Brittney Byer
- Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA
| | - Ursula K Mayer
- AniCura Kleintierspezialisten Augsburg, Augsburg, Germany
| | | |
Collapse
|
2
|
Byer B, Schlein LJ, Rose B, Séguin B. In-vitro effects of taurolidine alone and in combination with mitoxantrone and/or piroxicam on canine transitional cell carcinoma. Can J Vet Res 2020; 84:115-123. [PMID: 32255906 PMCID: PMC7088828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 06/06/2019] [Indexed: 06/11/2023]
Abstract
The objective of this in-vitro study was to evaluate taurolidine as a therapy for transitional cell carcinomas in canine patients. Transitional cell carcinoma (TCC) is the most common cancer of the urinary bladder in dogs and accounts for approximately 2% of reported malignancies in this species. There is no cure for this neoplasm and most dogs are lost from complications associated with progression of the local disease. Taurolidine has been shown to have anti-tumor and antiangiogenic effects against a variety of neoplasms in human and animal models. Four canine TCC cell lines were treated with various concentrations of taurolidine, mitoxantrone, and piroxicam alone. In addition, combinations of taurolidine/mitoxantrone, taurolidine/piroxicam, mitoxantrone/piroxicam, and taurolidine/mitoxantrone/piroxicam were assessed. Susceptibility of the TCC cell lines was based on a 72-hour growth inhibition assay using resazurin with absorbance measured at λ530/590. The ability of taurolidine to induce apoptosis was evaluated on 2 of the cell lines with an Annexin-V/propidium iodide assay. All cell lines were susceptible to treatment with taurolidine, mitoxantrone, and piroxicam alone. The results of the combination therapies of the 3 drugs were dependent on cell line and concentration and revealed no change in cell growth inhibition, a subadditive relationship, or a synergistic relationship. Taurolidine induced apoptosis in a concentration- and time-dependent fashion. Taurolidine alone showed significant effects on cell viability in vitro in canine TCC cell lines and these effects can be potentially enhanced with the addition of mitoxantrone and/or piroxicam.
Collapse
Affiliation(s)
- Brittney Byer
- Flint Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA
| | - Lisa J Schlein
- Flint Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA
| | - Barbara Rose
- Flint Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA
| | - Bernard Séguin
- Flint Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, Colorado 80523, USA
| |
Collapse
|
3
|
Lacassagne K, Hearon K, Berg J, Séguin B, Hoyt L, Byer B, Selmic LE. Canine spinal meningiomas and nerve sheath tumours in 34 dogs (2008-2016): Distribution and long-term outcome based upon histopathology and treatment modality. Vet Comp Oncol 2018; 16:344-351. [DOI: 10.1111/vco.12385] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 12/26/2017] [Accepted: 12/27/2017] [Indexed: 12/31/2022]
Affiliation(s)
- K. Lacassagne
- Department of Surgery; Veterinary Specialty Center of Seattle; Lynnwood Washington
| | - K. Hearon
- Department of Surgery; Metropolitan Veterinary Associates; Valley Forge Pennsylvania
| | - J. Berg
- Department of Neurology; Guardian Veterinary Specialists; Brewster New York
| | - B. Séguin
- Flint Animal Cancer Center; Colorado State University; Fort Collins Colorado
| | - L. Hoyt
- Department of Radiology; Blue Pearl; New York New York
| | - B. Byer
- College of Veterinary medicine and Biomedical Sciences; Colorado State University; Fort Collins Colorado
| | - L. E. Selmic
- Department of Veterinary Clinical Medicine, College of Veterinary medicine; University of Illinois Urbana-Champaign; Urbana Illinois
| |
Collapse
|
4
|
|
5
|
Holley JL, Monaghan J, Byer B, Bronsther O. An examination of the renal transplant evaluation process focusing on cost and the reasons for patient exclusion. Am J Kidney Dis 1998; 32:567-74. [PMID: 9774116 DOI: 10.1016/s0272-6386(98)70018-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A medical evaluation of prospective renal transplant recipients is performed to identify conditions that may exclude patients from transplantation because of unacceptable risks. Protocols for evaluating potential transplant candidates are available, but there is little information about reasons for excluding patients from transplantation. To assess the effectiveness and cost of our renal transplant-recipient evaluation process, we retrospectively reviewed patients excluded from renal transplantation between January 1993 and December 1995 to categorize the reasons for exclusion. We also examined the costs of the evaluation. The study group included all adults referred for kidney-only transplantation during the study period who were excluded from transplantation (n=125). Demographics of the 160 patients with end-stage renal disease (ESRD) who underwent renal transplantation during the study period were also examined. Compared with the patients who underwent transplantation, the excluded patients were older (48+/-14 v 43+/-12 years; P=0.006) and more likely to be women (66 of 125 patients; 53% v 57 of 160 patients; 36%; P=0.005) and diabetic (59 of 125 patients; 47% v 30 of 160 patients; 19%; P=0.005). The most common reason for excluding patients was medical contraindication (46%), followed by patient declined (25%), obesity (10%, defined as a body mass index [BMI] > or = 35), patient death (6%), and insurance/financial (5%). The medical reasons for exclusion were heart disease (38%), noncompliance (28%), miscellaneous (22%), and cancer (12%). Tests performed after the initial evaluation included cardiac testing (stress thallium or echocardiography and coronary angiography) in 50 patients, Doppler studies of the lower extremities in 28 patients, and hepatitis C polymerase chain reaction (PCR) or recombinant immunoblot assay (RIBA) assays in 8 patients. The cost of standard pretransplantation blood work for selected tests (ABO blood group typing, HLA, hepatitis B and C, and cytomegalovirus) was $709. Deferring such routine pretransplantation blood work until after the patient education session and history and physical examinations by nephrology and surgery in the 31 patients (25%) who declined transplantation at the initial visit would have resulted in considerable savings. Our evaluation process now includes prereferral information on a prospective recipient's medical problems, height and weight, and basic screening laboratory tests. This protocol has resulted in a more efficient and cost-effective evaluation process. Further examination of the cost-effectiveness of the transplant evaluation process is warranted.
Collapse
Affiliation(s)
- J L Holley
- Nephrology Unit of the University of Rochester Medical Center, NY 14642, USA.
| | | | | | | |
Collapse
|
6
|
Pabico RC, Yarger J, Byer B, Kremer M, McKenna BA, Cerilli GJ. Effects of cyclosporine A on chronic renal transplant rejection. Transplant Proc 1994; 26:2577-9. [PMID: 7940798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- R C Pabico
- Department of Medicine, University of Rochester School of Medicine and Dentistry, New York
| | | | | | | | | | | |
Collapse
|
7
|
Kissel S, Hoy W, Freeman R, Byer B, Yarger J. Renal Transplant Urinary Tract Infections. Effects of Perioperative Antibiotics and Earlier Catheter Removal. J Urol 1983. [DOI: 10.1016/s0022-5347(17)51212-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- S.M. Kissel
- Nephrology Unit, Strong Memorial Hospital, University of Rochester, Rochester, New York
| | - W.E. Hoy
- Nephrology Unit, Strong Memorial Hospital, University of Rochester, Rochester, New York
| | - R.B. Freeman
- Nephrology Unit, Strong Memorial Hospital, University of Rochester, Rochester, New York
| | - B. Byer
- Nephrology Unit, Strong Memorial Hospital, University of Rochester, Rochester, New York
| | - J.M. Yarger
- Nephrology Unit, Strong Memorial Hospital, University of Rochester, Rochester, New York
| |
Collapse
|
8
|
Kissel SM, Hoy WE, Freeman RB, Byer B, Yarger JM. Renal transplant urinary tract infections: effect of perioperative antibiotics and earlier catheter removal. N Y State J Med 1982; 82:1543-5. [PMID: 6755316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
9
|
Mirahmadi KS, Paul WL, Winer RL, Dabir-Vaziri N, Byer B, Gorman JT, Rosen SM. Serum ferritin level. Determinant of iron requirement in hemodialysis patients. JAMA 1977; 238:601-3. [PMID: 577960 DOI: 10.1001/jama.238.7.601] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Seventeen patients without renal failure and 14 patients receiving long-term hemodialysis were studied. Serum and bone marrow ferritin determinations were made at the time of bone marrow aspiration. A good correlation was found between serum ferritin levels and bone marrow iron stores, as well as between bone marrow ferritin levels and iron stores. Serum ferritin determinations appear to give an accurate estimation of bone marrow iron stores, thereby providing a reliable guide for iron replacement therapy and reducing the need for repeated bone marrow aspirations. Serum ferritin levels of less than 105 ng/ml suggest decreased iron stores, and values greater than 120 ng/ml indicate adequate or increased iron stores. Preliminary data also suggest that bone marrow ferritin determinations may be useful in quantitating bone marrow iron stores.
Collapse
|
10
|
|